New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:07 EDTCNCE, CELG, JAZZConcert Pharmaceuticals reports FY13 EPS ($4.99) vs. (16.15) last year
Concert Pharmaceuticals reports FY13 revenue $25.4M vs. $12.8M last year. The company said, "The increase in revenue was primarily due to license and research and development revenue of $17M and $3.7M recognized for the year ended December 31, 2013 in connection with collaborations entered into with Celgene (CELG) and Jazz Pharmaceuticals (JAZZ) respectively, during 2013."
News For CNCE;CELG;JAZZ From The Last 14 Days
Check below for free stories on CNCE;CELG;JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
07:48 EDTJAZZJazz Pharmaceuticals price target raised to $177 from $171 at Leerink
Leerink raised its price target for Jazz Pharmaceuticals shares to $177 citing an improved outlook for defibrotide. The firm keeps an Outperform rating on the stock.
July 28, 2014
11:36 EDTJAZZCANbridge Life Sciences and EUSA Pharma form agreement to commercialize Caphosol
CANbridge Life Sciences has entered into an exclusive partnership with EUSA Pharma, a Jazz Pharmaceuticals company, to commercialize CaphosolŪ in China. Under the terms of the agreement, CANbridge obtains exclusive rights to commercialize Caphosol in China, where over 3.5M new cancer cases are diagnosed each year, and there is little in the way of a standard adjunct therapy to treat oral mucositis. Caphosol is a prescription medical device, approved in the United States and European Union, designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx.
July 25, 2014
07:06 EDTCELGCelgene shares should recover, says Cantor
Subscribe for More Information
July 24, 2014
12:20 EDTCELGCelgene price target raised to $115 from $85 at Piper Jaffray
Subscribe for More Information
07:45 EDTCELGCelgene reports Q2 VIDAZA sales decreased 28%
Subscribe for More Information
07:43 EDTCELGCelgene reports Q2 ABRAXANE sales increased 39%
Subscribe for More Information
07:42 EDTCELGCelgene reports Q2 REVLIMID sales increased 15%
Subscribe for More Information
07:34 EDTCELGCelgene raises FY14 adjusted EPS view to $3.60-$3.65 from $3.50-$3.60
Consensus is $3.67. Raises FY14 revenue view to $7.6B from $7.5B, consensus $7.54B. Sees Revlimid net product sales $4.95B from preview $4.9B-$5B range. Sees Abraxane net product sales $850M-$900M.
07:32 EDTCELGCelgene reports Q2 adjusted EPS 90c, consensus 89c
Reports Q2 revenue $1.87B, consensus $1.85B.
July 23, 2014
15:30 EDTCELGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
09:41 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX FB MSFT CELG TWTR TSLA VALE CNW
08:29 EDTJAZZJazz Pharmaceutical initiated with a Buy at Buckingham
Target $215.
08:10 EDTJAZZDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTJAZZJazz Pharmaceuticals initiated with a Buy at Deutsche Bank
Subscribe for More Information
07:12 EDTCELGCelgene has upper hand in Revlimid case, says Bernstein
Subscribe for More Information
July 17, 2014
10:00 EDTJAZZOn The Fly: Analyst Initiation Summary
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use